INDIANAPOLIS, Oct. 2, 2024 /PRNewswire/ -- Ambetter Health, a product offered by a Centene Corporation (NYSE: CNC) company, which provides insurance to under-insured and uninsured populations in Indiana through the federal Health Insurance Marketplace®, will offer Indianans a variety of affordable health insurance plans to residents in all 92 counties for plan year 2025. Open enrollment for the Health Insurance Marketplace for Indiana runs from Nov. 1, 2024, through Jan. 15, 2025. Enroll by Dec. 15, 2024, for coverage starting Jan. 1, 2025.
"Ambetter Health has the experience and resources to provide comprehensive, quality care to people when it matters most," said MHS Plan President and Chief Executive Officer, Kevin O'Toole. "We're pleased to offer coverage options that provide peace of mind during this enrollment period."
Ambetter Health offers its members access to quality care, convenient services and valuable rewards. The 2025 benefits and offerings include:
Indiana residents interested in learning more about Ambetter Health or enrolling in a health plan during the open enrollment period may visit ambetterhealth.com/en/in/. Ambetter Health was formerly known in Indiana as Ambetter from MHS.
About Ambetter Health
Ambetter Health serves under-insured and uninsured populations through the federal Health Insurance Marketplace. Ambetter Health is underwritten by Coordinated Care Corporation and Celtic Insurance Company. Coordinated Care Corporation is a Qualified Health Plan issuer in Indiana. For more information, visit ambetterhealth.com/en/. This is a solicitation for insurance. For information on your right to receive an Ambetter Health plan free of discrimination, or your right to receive language, auditory and/or visual assistance services, please visit ambetterhealth.com/en/ and scroll to the bottom of the page.
Last Trade: | US$59.10 |
Daily Change: | 1.29 2.23 |
Daily Volume: | 4,074,504 |
Market Cap: | US$29.840B |
October 30, 2024 October 25, 2024 September 11, 2024 August 29, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB